Alkem signs license agreement with Harvard Universitys Office of Technology Development

17 Feb 2022 , 01:34 AM

Alkem Laboratories has signed a license agreement with Harvard Universitys Office of Technology Development OTD enabling Alkem to develop and commercialize a novel technology that may help meet the dire need for effective treatment of diabetic neuropathy foot ulcers peripheral arterial disease PAD and other injuries caused by vascular disease The license grants Alkem commercialization rights in the United States and India